Distinguishing incident and prevalent diabetes in an electronic medical records database

Pharmacoepidemiology and Drug Safety

Volumn 23, Issue 2, 2014, Pages 111-118

  Mamtani, Ronac ^a   Haynes, Kevin ^b   Finkelman, Brian S ^b   Scott, Frank I ^b   Lewis, James D ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Bias; Cohort studies; Diabetes; Electronic medical records; Incidence; Pharmacoepidemiology

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; INCRETIN; INSULIN; MEGLITINIDE; METFORMIN; SULFONYLUREA;

ADULT; AGE; AGED; ARTICLE; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE CLASSIFICATION; DISEASE DURATION; DISEASE REGISTRY; ELECTRONIC MEDICAL RECORD; FEMALE; FOLLOW UP; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; MORTALITY; OBESITY; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SEX; SMOKING;

BIAS; COHORT STUDIES; DIABETES; ELECTRONIC MEDICAL RECORDS; INCIDENCE; PHARMACOEPIDEMIOLOGY;

ADULT; AGED; COHORT STUDIES; DATABASES, FACTUAL; DIABETES COMPLICATIONS; DIABETES MELLITUS; ELECTRONIC HEALTH RECORDS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PREVALENCE; PROPORTIONAL HAZARDS MODELS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84892847494     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3557     Document Type: Article

References (42)

1. Hippisley-Cox J, Pringle M. Prevalence, care, and outcomes for patients with diet-controlled diabetes in general practice: cross sectional survey. Lancet Jul 31-Aug 6 2004; 364(9432): 423-428.
2. Reed M, Huang J, Graetz I, et al. Outpatient electronic health records and the clinical care and outcomes of patients with diabetes mellitus. Ann internal med Oct 2 2012; 157(7): 482-489.
3. Nichols GA, Desai J, Elston Lafata J, et al. Construction of a multisite DataLink using electronic health records for the identification, surveillance, prevention, and management of diabetes mellitus: the SUPREME-DM project. Prev Chronic Dis 2012; 9: E110.
4. Bosco JL, Antonsen S, Sorensen HT, Pedersen L, Lash TL. Metformin and incident breast cancer among diabetic women: a population-based case-control study in Denmark. Cancer Epidemiol Biomarkers Prev Jan 2011; 20(1): 101-111.
5. Azoulay L, Yin H, Filion KB, et al. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ 2012; 344: e3645.
6. Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA: the journal of the American Medical Association Jul 28 2010; 304(4): 411-418.
7. Bobo WV, Cooper WO, Stein CM, et al. Positive predictive value of a case definition for diabetes mellitus using automated administrative health data in children and youth exposed to antipsychotic drugs or control medications: a Tennessee Medicaid study. BMC Med Res Meth 2012; 12: 128.
8. Ho ML, Lawrence N, van Walraven C, et al. The accuracy of using integrated electronic health care data to identify patients with undiagnosed diabetes mellitus. J Eval Clin Pract Jun 2012; 18(3): 606-611.
9. Asghari S, Courteau J, Carpentier AC, Vanasse A. Optimal strategy to identify incidence of diagnostic of diabetes using administrative data. BMC Med Res Meth 2009; 9: 62.
10. Lewis JD, Bilker WB, Weinstein RB, Strom BL. The relationship between time since registration and measured incidence rates in the General Practice Research Database. Pharmacoepidemiol Drug Saf. Jul 2005; 14(7): 443-451.
11. Blanchard JF, Ludwig S, Wajda A, et al. Incidence and prevalence of diabetes in Manitoba, 1986-1991. Diabetes care Aug 1996; 19(8): 807-811.
12. Hux JE, Ivis F, Flintoft V, Bica A. Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. Diabetes care Mar 2002; 25(3): 512-516.
13. Kudyakov R, Bowen J, Ewen E, et al. Electronic health record use to classify patients with newly diagnosed versus preexisting type 2 diabetes: infrastructure for comparative effectiveness research and population health management. Population health manage Feb 2012; 15(1): 3-11.
14. Blak BT, Thompson M, Dattani H, Bourke A. Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. Inf primary care 2011; 19(4): 251-255.
15. Chisholm J. The Read clinical classification. BMJ Apr 28 1990; 300(6732): 1092.
16. Gonzalez EL, Johansson S, Wallander MA, Rodriguez LA. Trends in the prevalence and incidence of diabetes in the UK: 1996-2005. J Epidemiol Community Health Apr 2009; 63(4): 332-336.
17. Martin-Merino E, Fortuny J, Rivero E, Garcia-Rodriguez LA. Validation of diabetic retinopathy and maculopathy diagnoses recorded in a U.K. primary care database. Diabetes care Apr 2012; 35(4): 762-767.
18. Hall GC, McMahon AD, Carroll D, Home PD. Macrovascular and microvascular outcomes after beginning of insulin versus additional oral glucose-lowering therapy in people with type 2 diabetes: an observational study. Pharmacoepidemiol Drug Saf Mar 2012; 21(3): 305-313.
19. Mulnier HE, Seaman HE, Raleigh VS, Soedamah-Muthu SS, Colhoun HM, Lawrenson RA. Mortality in people with type 2 diabetes in the UK. Diabet Med May 2006; 23(5): 516-521.
20. Denburg MR, Haynes K, Shults J, Lewis JD, Leonard MB. Validation of The Health Improvement Network (THIN) database for epidemiologic studies of chronic kidney disease. Pharmacoepidemiol Drug Saf Nov 2011; 20(11): 1138-1149.
21. Lo Re V, 3rd, Haynes K, Forde KA, Localio AR, Schinnar R, Lewis JD. Validity of The Health Improvement Network (THIN) for epidemiologic studies of hepatitis C virus infection. Pharmacoepidemiol Drug Saf Sep 2009; 18(9): 807-814.
22. Lewis JD, Brensinger C, Bilker WB, Strom BL. Validity and completeness of the General Practice Research Database for studies of inflammatory bowel disease. Pharmacoepidemiol Drug Saf Apr-May 2002; 11(3): 211-218.
23. Mamtani R, Haynes K, Bilker WB, et al. Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study. J Natl Cancer Inst Sep 19 2012; 104(18): 1411-1421.
24. Haynes K, Forde KA, Schinnar R, Wong P, Strom BL, Lewis JD. Cancer incidence in The Health Improvement Network. Pharmacoepidemiol Drug Saf Aug 2009; 18(8): 730-736.
25. Larsson SC, Orsini N, Brismar K, Wolk A. Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia Dec 2006; 49(12): 2819-2823.
26. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat med Feb 15 2000; 19(3): 335-351.
27. Brunelli SM, Gagne JJ, Huybrechts KF, et al. Estimation using all available covariate information versus a fixed look-back window for dichotomous covariates. Pharmacoepidemiol Drug Saf May 2013; 22(5): 542-550.
28. Rubin D. Multiple Imputation for Nonresponse in Surveys. New York: Wiley; 1987.
29. Lin DY, Psaty BM, Kronmal RA. Assessing the sensitivity of regression results to unmeasured confounders in observational studies. Biometrics Sep 1998; 54(3): 948-963.
30. Suissa S, Azoulay L. Metformin and the risk of cancer: time-related biases in observational studies. Diabetes care Dec 2012; 35(12): 2665-2673.
31. Fox CS, Sullivan L, D'Agostino RB, Sr., Wilson PW. The significant effect of diabetes duration on coronary heart disease mortality: the Framingham Heart Study. Diabetes care Mar 2004; 27(3): 704-708.
32. Brun E, Nelson RG, Bennett PH, et al. Diabetes duration and cause-specific mortality in the Verona Diabetes Study. Diabetes care Aug 2000; 23(8): 1119-1123.
33. Banerjee C, Moon YP, Paik MC, et al. Duration of diabetes and risk of ischemic stroke: the Northern Manhattan Study. Stroke May 2012; 43(5): 1212-1217.
34. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch ophthalmol Apr 1984; 102(4): 527-532.
35. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int Jan 2003; 63(1): 225-232.
36. Young MJ, Boulton AJ, MacLeod AF, Williams DR, Sonksen PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia Feb 1993; 36(2): 150-154.
37. Hebert PL, Geiss LS, Tierney EF, Engelgau MM, Yawn BP, McBean AM. Identifying persons with diabetes using Medicare claims data. Am J Med Qual: Off J Amer College Med Qual Nov-Dec 1999; 14(6): 270-277.
38. Harris SB, Glazier RH, Tompkins JW, et al. Investigating concordance in diabetes diagnosis between primary care charts (electronic medical records) and health administrative data: a retrospective cohort study. BMC Health Serv Res 2010; 10: 347.
39. Khan NF, Harrison SE, Rose PW. Validity of diagnostic coding within the General Practice Research Database: a systematic review. Br J Gen Pract: J R College Gen Practitioners Mar 2010; 60(572): e128-136.
40. Hippisley-Cox J. Diabetes in the United Kingdom: Analysis of QRESEARCH data. 2007; http://www.qresearch.org/Public_Documents/DataValidation/Diabetes%20in%20the%20UK%20analysis%20of%20QRESEARCH%20data.pdf
41. Daousi C, Casson IF, Gill GV, MacFarlane IA, Wilding JP, Pinkney JH. Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors. Postgraduate med j Apr 2006; 82(966): 280-284.
42. Samaranayaka S, Gulliford MC. Trends in cardiovascular risk factors among people with diabetes in a population based study. Health Survey for England 1994-2009. Primary care diabetes May 16 2013.